ArticleDiscover oncology2026
Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBipolar androgen therapy (BAT) with supraphysiologic testosterone (SPT) could be a therapeutic platform to keep the “endocrine interference” going in men with castration resistant prostate cancer CRPC Davis ID., et al(N Engl J Med 38:121-31, 2019), Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC (Oncologist 28:465-73, 2023). This concept, scientifically developed by the Johns Hopkins group, has been tested in several clinical trials Denmeade SR, Isaacs JT (Prostate 70:1600-7, 2010). CASE PRESENTATION: This case report details the diagnosis and novel treatment with BAT during the course of disease of a 68-year-old male patient with primary metastatic prostate cancer identified in November 2019. After treatment failure of standard therapy this patient commenced with SPT given intramuscularly at four weeks intervals and concurrent androgen deprivation throughout treatment with BAT (Fig. 1). He responded clinically with stable disease and without serious toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.